

For healthcare and medical media

**BOSTON SCIENTIFIC'S TAXUS™ Liberté™ stent:**  
***The first second-generation drug-eluting coronary stent system***

The TAXUS™ Liberté™ coronary stent system is Boston Scientific's state-of-the-art, second-generation paclitaxel-eluting stent system. The TAXUS Liberté stent system combines the TAXUS system technology (paclitaxel and Translute™ polymer) with the innovative thin-strut Liberté™ stent platform, offering interventional cardiologists improved flexibility, conformability and deliverability in challenging vessel anatomies and complex lesions.<sup>1</sup>



***Strong clinical data support the excellent performance of TAXUS Liberté stent system***

The safety and efficacy of the TAXUS Liberté stent system has been confirmed in the extensive TAXUS ATLAS clinical trial. The workhorse trial compares clinical and angiographic data of patients receiving the TAXUS Liberté stent system with those of a matched control group from the TAXUS IV and V clinical trials using the TAXUS™ Express™ and the TAXUS™ Express<sup>2</sup>™ stent systems. The TAXUS ATLAS clinical program examined a broad range of patient types, from workhorse lesions, to small vessels and long lesions, as well as direct stenting of patients. Overall the TAXUS Liberté stent system showed improved acute performance over the TAXUS™ Express™ and the TAXUS™ Express<sup>2</sup>™ stent systems with over a 10% reduction in procedure time. The clinical outcomes

from the TAXUS ATLAS trial were similar to TAXUS™ Express™ and the TAXUS™ Express<sup>2</sup>™ stent systems even though the patients treated with the TAXUS Liberté stent system were more complex.

The TAXUS OLYMPIA Registry, one of the largest real-world registries, to date, with over 22,000 patients enrolled has shown similar safety and efficacy of the TAXUS Liberté Stent System in a real-world setting.

The TAXUS OLYMPIA results included 12-month data from the 529 patients in Phase I of the multi-phased registry and preliminary six-month data from the first 2,066 patients in Phase III. Both Phase I and Phase III patients exhibited a broad range of lesion and procedural complexity, reflecting “real world” usage patterns seen in everyday clinical practices. OLYMPIA registry Phase I 12-month findings demonstrated an overall TAXUS Liberté stent-related cardiac event rate of 3.7 percent, including myocardial infarction (1.4 percent), and TAXUS Liberté stent-related re-intervention of the target vessel (1.9 percent). Overall cardiac death was 1.5 percent.

Other large real-world registry data confirm the excellent clinical outcomes with the TAXUS Liberté stent system. The Swedish SCAAR Registry presented at ACC 2008 reported a similarly low 3 year revascularization rate for the TAXUS Liberté stent system.

### **Improved features of the Liberté stent platform**

The Liberté stent platform features the Veriflex™ stent design, which has a highly flexible cell geometry with thin struts and uniform cell distribution for improved conformability and deliverability.<sup>1</sup> In addition, the use of the enhanced TrakTip™ catheter tip with low lesion-entry profile, mounted on the Maverick<sup>2</sup>™ delivery catheter, provides enhanced lesion crossability.<sup>2</sup>

### **European and U.S. approval status**

The TAXUS Liberté stent system is approved for the treatment of de novo coronary lesions in Europe and in 18 other international markets in South America and Asia Pacific. TAXUS™ Liberté™ paclitaxel-eluting coronary stent system has received specific European CE Mark approval for use in patients with diabetes<sup>†</sup>. Boston Scientific submitted data showing the TAXUS Liberté stent has benefited diabetic patients with coronary artery disease, both in clinical trials and real-world registries. This approval means the TAXUS Liberté stent system now has more CE Mark-

approved indications than any other drug-eluting stent, allowing treatment of a wide range of patients including many of those at high risk. The TAXUS Liberté stent system has one of the largest drug-eluting stent matrices with 60 sizes available. The TAXUS Liberté Long stent (38 mm) has a unique advantage of being one of a few “long” stents available for patients and physicians in order to avoid overlapping multiple stents. The TAXUS Long stent has been shown to significantly reduce MI and to reduce procedure time. Boston Scientific completed the filing for pre-marketing approval of TAXUS Liberté with the U.S. Food and Drug Administration (FDA) in March 2006.

*The TAXUS Liberté stent system is not available for sale in the United States.*

<sup>1</sup> *Based on internal bench testing (n=3). Data on file.*

<sup>2</sup> *3.0 mm stents.*

\* For patients with concomitant diabetes mellitus

###

For further enquiries, please contact:

Geraldine Varoqui  
Boston Scientific PR Manager  
Tel: +49 2102 489 461  
[varoqui@bsci.com](mailto:varoqui@bsci.com)

OR

Tracy Paul  
BSC press office  
Tel: + 44 20 7413 3101  
[tpaul@medicalknowledgegroup.com](mailto:tpaul@medicalknowledgegroup.com)